CAL
CLDX icon

Capital Advisors Ltd’s Celldex Therapeutics CLDX Stock Holding History

Capital Advisors Ltd’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1
– – ﹤0.01% 1391
2026
Q1 		$0 Hold
1
– – ﹤0.01% 1393
2025
Q4 		$0 Hold
1
– – ﹤0.01% 1377
2025
Q3 		$0 Hold
1
– – ﹤0.01% 1378
2025
Q2 		$0 Buy
+1
New +$19 ﹤0.01% 1366

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Capital Advisors Ltd's CLDX Position: Q2 2026 in Review

Capital Advisors Ltd held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

Capital Advisors Ltd first reported a position in CLDX in Q2 2025 and has held it in 5 quarters since. 16 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Capital Advisors Ltd held 1 share of Celldex Therapeutics worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1391 holding.
  • Capital Advisors Ltd first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 16 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.